CR10921A - Moleculas de transporte que utilizan polipeptidos hiv-tat de secuencia inversa - Google Patents

Moleculas de transporte que utilizan polipeptidos hiv-tat de secuencia inversa

Info

Publication number
CR10921A
CR10921A CR10921A CR10921A CR10921A CR 10921 A CR10921 A CR 10921A CR 10921 A CR10921 A CR 10921A CR 10921 A CR10921 A CR 10921A CR 10921 A CR10921 A CR 10921A
Authority
CR
Costa Rica
Prior art keywords
transport molecules
inverse sequence
tat polypeptides
sequence hiv
molecules
Prior art date
Application number
CR10921A
Other languages
English (en)
Inventor
Jacob M Waugh
Jae Hoon Lee
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CR10921A publication Critical patent/CR10921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invencion se relaciona con moleculas de transporte novedosas que comprenden un polipeptido que comprende residuos de aminoacidos dispuestos en una secuencia que es la secuencia inversa de la porcion basica de la proteina HIV-TAT. Los polipeptidos de transporte novedosos son utiles para el suministro intracelular o de transmembrana de las moleculas de carga, ejemplos no limitantes de los cuales incluyen polipeptidos y acidos nucleicos.
CR10921A 2006-12-29 2009-07-13 Moleculas de transporte que utilizan polipeptidos hiv-tat de secuencia inversa CR10921A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88263906P 2006-12-29 2006-12-29

Publications (1)

Publication Number Publication Date
CR10921A true CR10921A (es) 2009-09-14

Family

ID=39589169

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10921A CR10921A (es) 2006-12-29 2009-07-13 Moleculas de transporte que utilizan polipeptidos hiv-tat de secuencia inversa

Country Status (16)

Country Link
US (2) US20080226551A1 (es)
EP (1) EP2109363A4 (es)
JP (2) JP2010514779A (es)
KR (1) KR20090102833A (es)
CN (1) CN101583274A (es)
AR (1) AR064707A1 (es)
AU (1) AU2007340158A1 (es)
BR (1) BRPI0720729A2 (es)
CA (1) CA2672886C (es)
CO (1) CO6220837A2 (es)
CR (1) CR10921A (es)
MX (1) MX2009007070A (es)
NO (1) NO20092697L (es)
NZ (1) NZ598159A (es)
TW (1) TW200848080A (es)
WO (1) WO2008082885A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
WO2006094263A2 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
HRP20161722T1 (hr) 2007-07-26 2017-02-10 Revance Therapeutics, Inc. Antimikrobni peptid i njegovi pripravci
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
WO2010047216A1 (ja) 2008-10-23 2010-04-29 国立大学法人 東京大学 microRNAの機能阻害法
WO2010114828A1 (en) 2009-04-01 2010-10-07 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
IL271845B2 (en) 2017-07-13 2024-06-01 Michael David Forrest Therapeutic modulators of the reverse mode of atp synthase
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6986893B2 (en) * 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
CA2291074C (en) * 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
CN1281512A (zh) * 1997-12-12 2001-01-24 昂尼克斯药物公司 p53+肿瘤细胞的选择性杀伤和诊断
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6261679B1 (en) * 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
TR200100254T2 (tr) * 1998-07-13 2001-06-21 Expression Genetics, Inc. Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.
US6280937B1 (en) * 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000024419A1 (en) * 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) * 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) * 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
MXPA03007358A (es) * 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
AUPR621501A0 (en) * 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
WO2003011333A1 (en) * 2001-07-27 2003-02-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
WO2003041128A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
CA2469336C (en) * 2001-12-11 2013-06-11 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
WO2003066859A2 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
EP1572941A4 (en) * 2002-02-26 2009-03-18 Maxygen Inc NEW FLAVIVIRUS ANTIGENES
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
GB0216414D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US7504211B2 (en) * 2002-08-27 2009-03-17 Bristol-Myers Squibb Company Methods of using EPHA2 for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
EP1629105B1 (en) * 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
CA2558408C (en) * 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
KR100852824B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
WO2006094263A2 (en) * 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8114581B2 (en) * 2005-09-15 2012-02-14 The Regents Of The University Of California Methods and compositions for detecting neoplastic cells
CN101374860A (zh) * 2005-12-23 2009-02-25 技术转让合伙人公司 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
HRP20161722T1 (hr) * 2007-07-26 2017-02-10 Revance Therapeutics, Inc. Antimikrobni peptid i njegovi pripravci
ES2669020T3 (es) * 2008-12-31 2018-05-23 Revance Therapeutics, Inc. Formulaciones inyectables de toxina botulínica

Also Published As

Publication number Publication date
EP2109363A2 (en) 2009-10-21
US20100093639A1 (en) 2010-04-15
NO20092697L (no) 2009-09-28
BRPI0720729A2 (pt) 2014-04-08
NZ598159A (en) 2013-08-30
CA2672886A1 (en) 2008-07-10
AR064707A1 (es) 2009-04-22
MX2009007070A (es) 2009-07-10
TW200848080A (en) 2008-12-16
US20080226551A1 (en) 2008-09-18
CN101583274A (zh) 2009-11-18
JP2010514779A (ja) 2010-05-06
WO2008082885A2 (en) 2008-07-10
EP2109363A4 (en) 2014-07-09
KR20090102833A (ko) 2009-09-30
CO6220837A2 (es) 2010-11-19
CA2672886C (en) 2015-02-10
JP2014012680A (ja) 2014-01-23
WO2008082885A3 (en) 2008-11-20
AU2007340158A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
AR064707A1 (es) Moleculas de transorte utilizando polipeptidos hiv -tat de secuencia inversa
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
ES2512141T3 (es) Análogo peptídico de oxintomodulina
UY31123A1 (es) Proteinas de fusion natriureticas
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
EP2176289A4 (en) INSULINOTROPES PEPTIDE DERIVATIVITY WITH MODIFIED N-TERMINAL AMINO ACID
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CY1117710T1 (el) Κρυσταλλικοι αναστολεις πρωτεασων εποξυ-κετονων πεπτιδιων και η συνθεση των κετο-εποξειδιων αμινοξεων
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
CY1117351T1 (el) Κυτταροδιαπερατοι αναστολεις πεπτιδιων της jnk-σηματοδοτικης πορειας μεταγωγης
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
CL2007002157A1 (es) Proteina de fusion que comprende una exendina-4 fusionada a una transferrina; acido nucleico, vector y celula huesped que codifican dicha proteina; composicion farmaceutica que comprende dicha proteina; y uso de la proteina de fusion para tratar diab
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
ATE482281T1 (de) Plastiden transit peptide
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
PE20131141A1 (es) Anticuerpo monoclonal
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
PE20171336A1 (es) Anticuerpos contra tau y sus usos
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide